158 related articles for article (PubMed ID: 12694074)
1. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.
Weill D; Lock BJ; Wewers DL; Young KR; Zorn GL; Early L; Kirklin JK; McGiffin DC
Am J Transplant; 2003 Apr; 3(4):492-6. PubMed ID: 12694074
[TBL] [Abstract][Full Text] [Related]
2. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
3. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
Zamora MR
Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
5. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
8. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
9. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.
Zamora MR; Nicolls MR; Hodges TN; Marquesen J; Astor T; Grazia T; Weill D
Am J Transplant; 2004 Oct; 4(10):1635-42. PubMed ID: 15367218
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
[TBL] [Abstract][Full Text] [Related]
11. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
12. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
14. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
Tzakis AG
Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir.
Brumble LM; Milstone AP; Loyd JE; Ely EW; Pierson RN; Gautam S; Dummer JS
Chest; 2002 Feb; 121(2):407-14. PubMed ID: 11834650
[TBL] [Abstract][Full Text] [Related]
19. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
[TBL] [Abstract][Full Text] [Related]
20. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
